In addition to collaborations, starting on July 1, 2025, Novo Nordisk is also introducing a new cash-offer price of $299 available through July 31, 2025. This $299 introductory price is available for self-paying patients who are new to the Wegovy^® savings offer or those who have not previously filled a prescription through NovoCare^® Pharmacy. This builds on the previous $199 Wegovy^® cash-offer patient price that expires on June 30, 2025. Patients who redeemed the $199 Wegovy^® savings offer between May 22 and June 30, 2025, will be eligible for the $299 price on one fill between July 1 and July 31. For subsequent months, self-paying patients will pay $499 per month.

Patients can access this offer in multiple ways: 

• Patients can activate their one-time offer at Wegovy.com, then either print or have it sent straight to their phone prior to visiting their pharmacy of choice.
• These savings will also be available through WeightWatchers, Ro, and LifeMD, the telehealth providers integrated with NovoCare^®Pharmacy, allowing them to pass the savings along to their customers in line with their offerings and services.
• The savings offer is also available through NovoCare^® Pharmacy. CenterWell Pharmacy is the dispensing pharmacy managing prescription fulfillment and delivery for NovoCare^® Pharmacy.

With all doses of FDA-approved Wegovy^® fully available nationwide, it is illegal under U.S. compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptions. Novo Nordisk continues to build on existing efforts and identify new options that help all patients, regardless of where they choose to access authentic, FDA-approved Wegovy^® as part of our relentless focus on patient safety.

The FDA has warned that "serious patient illnesses and deaths have been linked to poor quality compounded drugs" and that knockoff compounded "semaglutide" can be risky and dangerous. Essentially all "semaglutide" used in compounding is manufactured by foreign suppliers in China and can use illicit active pharmaceutical ingredients. According to Novo Nordisk's analysis, more than half of the Chinese suppliers that shipped "semaglutide" into the U.S. for compounding or further manufacturing in 2024 and so far in 2025 are not even permitted to manufacture "semaglutide" for use in drugs for patients in China. Novo Nordisk has already filed nearly 120 lawsuits across 34 states against entities who unlawfully market or sell knockoff drugs. We will continue pursuing legal action against bad actors and working closely with law enforcement and regulators to prevent illegal activity and protect patients from the risks posed by unapproved knockoff drugs and foreign illicit active pharmaceutical ingredients.